The Science Board will hear about and provide input regarding the Centers for Excellence in Regulatory Science and Innovation. The Science Board will also hear an update regarding the Scientific Computing/JANUS program. FDA’s Modernizing Toxicology Working Group will present an overview to the Science Board for input and discussion. The Center for Drug Evaluation and Research will provide their response to the May 2011 Subcommittee Report regarding the Review of the FDA/CDER Pharmacovigilance Program. The Board will be provided with an update from Subcommittee for the science review of the Center for Devices and Radiological Health.
Jan. 6, 2012
9:00 a.m. – 3:15 p.m.
Food and Drug Administration
10903 New Hampshire Ave.
Bldg. 31, Rm. 1503
Silver Spring, MD 20993-0002
Visitors to the White Oak Campus must enter through Building 1.
For those unable to attend in person, the meeting will be webcast.
Meeting Materials
-
Background material should be available no later than two days before the meeting: 2012 Meeting Materials, Science Board to the FDA
If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting.
Contact Information
Martha Monser
Office of Chief Scientist
Office of the Commissioner
Food and Drug Administration
White Oak Bldg 32, Room 4286
10903 New Hampshire Ave.
Silver Spring, Maryland 20993
Phone: 301–796-4627
Fax: 301-847-8617
E-mail: martha.monser@fda.hhs.gov